Clinical trials: SARS-CoV-2, COVID-19
Moderate COVID-19 Pneumonia, Severe COVID-19 Pneumonia, Pneumonia, Viral
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
Due to the limitations of COVID-19 treatment and in the absence of licensed antiviral for COVID-19, the historical choice of therapeutic convalescent plasma (CP) is considered especially against RNA viruses .It was known that…
- Trial name
- NCT04474340
- Testing
- COVID-19 Convalscent Plasma
- Where
- Kuwait
- Volunteers
- 300 people
- Sponsor
- Ministry of Health, Kuwait
Covid-19
COVID-19 Virtual Care at Home
This multicentre prospective cohort trial is designed to demonstrate effectiveness and efficiency of a virtual care model for the management of COVID-19 patients isolating at home.
- Trial name
- NCT04420182
- Testing
- Virtual Care at Home
- Where
- 5 sites in Canada
- Volunteers
- 817 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
COVID-19
PROLIFIC ChemoprophylaxisTrial (COVID-19)
The number of confirmed cases of COVID-19 infectious disease arising from the SARS-CoV-2 coronavirus is rising substantially and rapidly, with the potential to overwhelm the ability of the entire National Health Service (NHS) to…
- Trial name
- NCT04352933
- Testing
- Hydroxychloroquine - Daily dosing, Hydroxychloroquine - Weekly Dosing
- Where
- United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Covid19
Covid-19 Rapid Diagnostic Tests on Blood Drop
This study will evaluate the diagnostic reliability of the Biosynex rapid blood test for Covid-19 infection.
- Trial name
- COVID-TEST (NCT04467008)
- Where
- France
- Volunteers
- 113 people
- Sponsor
- CMC Ambroise Paré
Covid19, Depression
Depression and Anxiety in Long Term Coronavirus Disease COVID-19
Background : Depression and Anxiety are linked to COVID (Coronavirus Disease)-19 long-term impact through several mechanisms. The possible way is the alteration of neurotransmitter regulation from the interaction of severe acute…
- Conditions
- Covid19, Depression, Anxiety
- Trial name
- DALT-COV (NCT04893668)
- Testing
- Depression, Anxiety
- Where
- Indonesia
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Hasanuddin University
SAR-CoV-2, Cellular Immune Response
Study of Immune Response in Subjects Vaccinated Against SARS-CoV-2 Infection
Twelve months after the first SARS-CoV-2 cases in Wuhan, the FDA approved the first COVID-19 vaccine (Pfizer-BioNTech). Early studies on healthcare workers showed that antibody levels, especially against the Spike protein…
- Conditions
- SAR-CoV-2, Cellular Immune Response, Antibody Response
- Trial name
- BioVAC-immunit (NCT07049497)
- Testing
- Evaluation of the T cell response in terms of IFN-γ measured by ELISpot
- Where
- Italy
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Kidney Transplantation, SARS-CoV-2 Acute Respiratory Disease
Safety and Immunogenicity of 2-dose Inactivated COVID-19 Vaccine in Kidney Transplant Recipients
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a major impact on transplant recipients, with mortality rates up to 20%.
- Conditions
- Kidney Transplantation, SARS-CoV-2 Acute Respiratory Disease, Vaccine
- Trial name
- NCT04969614
- Volunteers
- 300 people
- Sponsor
- West China Hospital
Covid19, SARS-CoV Infection
COVID-19 IgG Formation in Physicians at ALGH and Their Household Members
This study is a community hospital-based study that will enhance information being obtained in similar studies taking place in France, Denmark, and China.
- Conditions
- Covid19, SARS-CoV Infection, Communicable Disease
- Trial name
- NCT04540484
- Testing
- Screening
- Where
- United States
- Volunteers
- 507 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
COVID-19, SARS-CoV-2
Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19)
The human monoclonal antibody CB6 showed potent neutralization activity in vitro against SARS-CoV-2. CB6-LALA (also called JS016) has been developed for clinical use.
- Trial name
- NCT04931238
- Testing
- JS016
- Where
- 4 sites in China
- Volunteers
- 200 people
- Sponsor
- Peking Union Medical College Hospital
Corona Virus Infection
COVID-19 Antigen Rapid Test Evaluation in Low-Prevalence Setting
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting COVID-19 pandemic present important diagnostic challenges.
- Trial name
- CV006 (NCT05911074)
- Testing
- The Abbott Panbio™ COVID-19 Ag Rapid Test
- Where
- Botswana
- Volunteers
- 7,274 people, healthy volunteers welcome
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
COVID19
Characteristics of Critically Ill COVID 19 Patients
COVID19 is n outbreak with unpredictable outcome
- Trial name
- NCT04465058
- Testing
- COVID19
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
COVID-19
Seroprevalence of Infection-induced SARS-CoV-2 Antibodies (COVID-19) in Children
It is unknown what proportion of children have been exposed to SARS-CoV-2 and how many have antibodies among children seeking medical care for non-Covid-19 related conditions.
- Trial name
- NCT05358626
- Testing
- SARS-CoV-2 IgG Antibody testing
- Where
- Vietnam
- Volunteers
- 4,032 people
- Sponsor
- National Children's Hospital, Vietnam
COVID-19 Pandemic, Diabetes
Study on the Effect of Incentive Spirometer-based Respiratory Training on the Long COVID-19
The COVID-19 pandemic has emerged as the most significant public health crisis of the 21st century. As of the end of January 2023, global confirmed cases have exceeded 670 million, with a domestic cumulative total of 10.24…
- Conditions
- COVID-19 Pandemic, Diabetes, Hypertension, Cardiac Disease
- Trial name
- NCT06231225
- Testing
- Incentive Spirometer respiratory training
- Volunteers
- 100 people
- Sponsor
- National Taipei University of Nursing and Health Sciences
SARS-CoV-2
Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021
This is an open-label study enrolling healthy adults that participated in Study ARCT-021-01 (the Parent Study). Participants will receive either a single injection of ARCT-021 or no injection and be followed for up to 365 days.
- Trial name
- NCT04728347
- Testing
- ARCT-021
- Where
- Singapore
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
COVID-19
Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination
Bacillus Calmette-Guérin (BCG) vaccine not only protects against tuberculosis, but has also been shown to induce protection against various infections with a viral aetiology, leading to significant reductions in morbidity and…
- Trial name
- NCT04417335
- Testing
- BCG vaccine
- Where
- 2 sites in Netherlands
- Volunteers
- 2,014 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Covid19
Characterisation of the Immune Response to SARS-CoV-2 / COVID-19
Emerging clinical details of the current SARS-CoV-2 pandemic have illustrated that there are multiple clinical presentations and outcomes of this viral infection.
- Trial name
- NCT04729452
- Testing
- blood test
- Where
- United Kingdom
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Cwm Taf University Health Board (NHS)
SARS-CoV-2 Acute Respiratory Disease, SARS-CoV-2 Sepsis
The Corona Study of Middle Norway
CUT COVID is a cohort study establised to collect information on patients hospitalized because or with infection by SARS-CoV-2. The cohort data includes clinical data and biological samples from multiple timepoints during…
- Conditions
- SARS-CoV-2 Acute Respiratory Disease, SARS-CoV-2 Sepsis, SARS CoV 2 Infection
- Trial name
- CUT COVID-19 (NCT05638178)
- Testing
- No intervention
- Where
- 5 sites in Norway
- Volunteers
- 223 people
- Sponsor
- St. Olavs Hospital
COVID-19
Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ/Ⅱ clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04352608
- Testing
- Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule, Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule, Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
- Where
- China
- Volunteers
- 744 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)
The purpose of the study is to determine if Liquid Alpha1-Proteinase Inhibitor (Human) (Liquid Alpha1-PI) plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day…
- Trial name
- NCT04547140
- Testing
- Liquid Alpha1-Proteinase Inhibitor (Human), Standard Medical Treatment
- Where
- 20 sites in United States, Brazil and 3 more
- Volunteers
- 57 people
- Sponsor
- Grifols Therapeutics LLC
COVID-19 Acute Respiratory Distress Syndrome
Rehabilitation of Critically Ill Patients With SARS-CoV-2 Variants in ICU With Limited Resources
Acute rehabilitation in critically ill patients can improve post-intensive care unit (post-ICU) physical function. Scientific evidence has considered neuromuscular electrical stimulation (NMES) as a promising approach for the…
- Trial name
- NCT05450120
- Testing
- Functional Rehabilitation, Neuromuscular Electrical Stimulation
- Where
- Brazil
- Volunteers
- 88 people
- Sponsor
- Universidade Federal de Sao Carlos
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.